Clinical Study Results
How has this study helped patients and
researchers?
This study helped researchers learn about the safety of durvalumab given with
tremelimumab or AZD9150 in participants who have relapsed or refractory
lymphoma.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with the combination of durvalumab, tremelimumab, and
AZD9150 are not planned.
11